Mission Bio

Mission Bio is a biotechnology startup focused on precision genomics with a mission to enable the discovery, development, and delivery of precision medicine. The company's Tapestri® Platform, described as the only technology providing single-cell targeted DNA sequencing at single-base resolution, showcases their innovative approach to solving complex biological problems.

Founded in 2012, Mission Bio originated from the high-throughput biology lab at the University of California, San Francisco (UCSF). The company's roots are grounded in the pioneering droplet microfluidics work, reflecting a strong foundation in precision engineering and biochemistry.

The latest milestone for Mission Bio is the $40.00M debt financing investment received on 01 January 2022, signaling confidence in the company's potential. While the specific investors are not disclosed, the investment underscores the industry's recognition of Mission Bio's innovative approach and the potential impact of their technology in the fields of biotechnology and healthcare.

Mission Bio's dedication to unlocking single-cell biology aligns with the growing interest in precision medicine, positioning the company as a key player in shaping the future of genomics. With a strong emphasis on precision and innovation, Mission Bio presents an intriguing opportunity for investors looking to engage in the evolving landscape of biotechnology and healthcare.